D-1071-2019 Class III Terminated

Recalled by Pfizer Inc. — New York, NY

FDA drug recall D-1071-2019 was initiated by Pfizer Inc. on Mar 15, 2019 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time point The recall status is terminated (terminated Aug 11, 2022). Affected quantity: 8,878 cartons (25 vials per carton).

Recall details

Product Type
Drugs
Report Date
Apr 10, 2019
Initiation Date
Mar 15, 2019
Termination Date
Aug 11, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
8,878 cartons (25 vials per carton)

Product description

Clindamycin Injection, USP, 600 mg/ 4 mL (150 mg/mL), 4 mL vials, Rx only, Distributed by: Alvogen, Inc., Pine Brook, NJ 07058 USA, NDC 47781-620-94

Reason for recall

Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time point

Distribution pattern

Nationwide USA and Guam

Code information

Lot #: T97496, Exp.04/2019, T97497, Exp.07/2019, W28564(exp 09/2019), W31812, Exp. 10/2019.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1071-2019
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1071-2019. Report a data issue: hello@regdatalab.com.